Navigation Links
MIT works toward novel therapeutic device
Date:10/22/2007

CAMBRIDGE, Mass.-MIT and University of Rochester researchers report important advances toward a therapeutic device that has the potential to capture cells as they flow through the blood stream and treat them. Among other applications, such a device could zapp cancer cells spreading to other tissues, or signal stem cells to differentiate.

Their concept leverages cell rolling, a biological process that slows cells down as they flow through blood vessels. As the cells slow, they adhere to the vessel walls and roll, allowing them to sense signals from nearby tissues that may be calling them to work. Immune cells, for example, can be slowed and summoned to battle an infection.

Through mimicking a process involved in many important physiological and pathological events, we envision a device that can be used to selectively provide signals to cells traveling through the bloodstream, said Jeffrey M. Karp of the Harvard-MIT Division of Health Sciences and Technology. This technology has applications in cancer and stem cell therapies and could be used for diagnostics of a number of diseases.

The team, led by Karp, started with technology to induce cell rolling for research. With an implantable therapeutic device in mind, they improved that cell rolling technology to make it safe, more stable and longer lasting.

The improvements are described in the October 20 online issue of the journal Langmuir, published by the American Chemical Society.

In the body, P-selectin and other selectin proteins regulate cell rolling in blood vessels. When P-selectin is present on a vessel's inner wall, cells that are sensitive to it will stick to that patch and begin to roll across it.

To induce rolling in the laboratory, the original technology weakly adheres P-selectin to a glass surface and flows cells across it. This surface treatment remains stable for several hours then breaks down. While this method is useful for experiments, it's not good for long-term stability, said Karp. An implantable device needs a coating that lasts weeks or even months so that patients won't need to come in frequently for replacements.

To improve the technology, the team experimented with several chemical methods to immobilize P-selectin on a glass surface. They identified a polyethelene glycol (PEG) coating that strongly bonded to P-selectin. This coating is also non-fouling, meaning it does not react with or accumulate other proteins, so it is potentially safe for use in an implant.

P-selectin remains stable on this coating for longer than the original technology. In tests with microspheres coated with a molecule that interacts with P-selectin, these spheres slowed down significantly as they flowed over the surface coated with layers of PEG and P-selectin. The effect was stable past four weeks, the longest the devices have been tested.

To validate that this technology works with cells that are sensitive to P-selectin, the team flowed neutrophils (white blood cells) across the coated surface. They too slowed and rolled on surfaces treated with the new coating, and the effect again lasted for at least four weeks.

The next step is translating these results to animal studies and using the technology to slow and capture stem cells and cancer cells circulating in the blood stream.

Ultimately CellTraffix, Inc., a sponsor of this technology and its licensee, wants to apply the technique to a device that is either implanted into the blood stream or appended as a shunt. In addition to PEG and selectin molecules, the device would also include a therapeutic agent. Such an agent would interact only with certain cells for a specific purpose.

According to University of Rochester biomedical engineering professor Michael King, who developed the concept for adhesive capture and reprogramming of cells, the device could, for example, slow down metastatic, or spreading, cancer cells and kill them.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Fireworks can spell death for asthmatic children
2. How a mans mind really works
3. Drug Combo Works Better for children with ADHD, Tics
4. How brain works
5. Meditation Works Medically
6. A first in Liver Transplant in India – Networking works wel
7. Warts: Spanner in Lovers Works!
8. Shot Supply: Reduced Dosage of Seasonal flu Vaccine, Works!
9. Subliminal Advertising works
10. De-addiction Drug Works For Alcoholics Too
11. Vagal Nerve Stimulation Works To Treat Severe Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... CT (PRWEB) , ... March 22, 2017 , ... ... historic plan to cure Rett Syndrome, a devastating neurological disorder that afflicts 350,000 ... MECP2, located on the X chromosome, and almost exclusively strikes females. Following ...
(Date:3/22/2017)... ... 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the ... in need of skilled pediatric dentistry in Rock Hill, SC, without a ... routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. ...
(Date:3/22/2017)... York (PRWEB) , ... March 22, 2017 , ... ... Hospital have entered into a research collaboration to translate advances in basic neuroscience ... impairments at Blythedale and beyond. The collaboration seeks to improve movement, vision, and cognition ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical ... immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small ...
(Date:3/22/2017)... ... March 22, 2017 , ... SNL Insurance ... to families and business owners in the greater Hampton Roads area, is embarking ... Society Relay For Life event. , Each year, hundreds of people living in ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 FinancialBuzz.com News ... According to ... was worth an estimated $6.6 billion in 2016, and is projected ... or reaching more than $24 billion by 2025. The medical cannabis ... growing from $4.7 billion in 2016, to an estimated $13.3 billion ...
(Date:3/22/2017)... 2017 EMD Serono, the biopharmaceutical business of Merck ... and Canada , today announced two new ... session at the 65 th Annual Pacific Coast Reproductive ... on March 24 th .   The results ... collected from July 2009 to December 2015 containing data from ...
(Date:3/22/2017)... MarketNewsUpdates.com News Commentary  ... As ... oil continues to rise in popularity with consumers, Cannabis ... enhancing production through acquiring innovative assets and other plant ... include: Future Farm Technologies Inc (OTC: FFRMF) (CSE: FFT.CN), mCig, ...
Breaking Medicine Technology: